… Therefore, new drugs, especially molecular targeting agents—… To use molecular targeting
agents including TKIs, there are … molecular targeting therapy for hematological malignancies, …

… Molecular targeting therapies for hematological malignant diseases such as monoclonal
antibodies and small molecules have been reviewed. Imatinib mesylate (STI571) targets the …

… In addition to the advances with mAb therapy, molecular targeting of hematologic
malignancies, primarily chronic myelogenous leukemia (CML), through specific tyrosine kinase …

… treatment of hematological malignancies have led to the more frequent usage of MoAbs in
the therapy. … Today, targeted therapy, based on selective inhibition of molecules, is becoming …

… received the Orphan Drug Designation for the treatment of … therapeutic target for the treatment
of BPDCN, while a possible in the treatment of AML and other hematological malignancies …

… on IAP molecular biology… targeting agents for treatment of hematological malignancies.
Keywords: Apoptosis, inhibitor of apoptosis proteins, IAPs, hematological malignancies, therapies…

… treatments clinically used for solid tumors. The presence and drug resistance nature of
cancer … The development of new treatments like molecular targeted drugs and antibodies has …

… therapy with small molecule inhibitors targeting these activated … targeted therapy of
hematologic malignancies, which include not only inactivation of the mutated PTK, but also targeting …

… Molecular target therapy is a recently rapid progress in the management of hematological
malignancies. In myeloid neoplasm, the sensational response to treatment and the overall …

… activation of pivotal molecules in the pathways may provide us with such specificity and
selectivity. A number of translocations occurring in hematological malignancies are known to …